/Insulet%20Corporation%20insulin%20monitor-by%20Maria%20Wan%20via%20Shutterstock.jpg)
Insulet Corporation (PODD), headquartered in Massachusetts, develops and markets the Omnipod Insulin Management System, which includes a small, tubeless, disposable insulin pump and a wireless Personal Diabetes Manager (PDM). The company is valued at $13.6 billion by market cap. The leading drug manufacturer plans to release its Q2 earnings for fiscal 2024 on Thursday, Aug. 8, after the market closes.
Ahead of the event, analysts expect Insulet to report a profit of $0.56 per share, up 47.4% from $0.38 per share in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of the last four quarters.